my thinking also, page-5

Thanks Dirk and Treasure for your posts. A couple of points l'd like to add regarding the split and value to be ascribed to existing shares with onco value.

RBS who are well in bed with our company valued oncology at .30c earlier this year so we should use this as the benchmark rather than your suggestion dirk/treasure of 12c on a 40:1 ratio. This then becomes far more palatable. 12c would be downright robbery as far as l'm concerned paticularly in the light of an ipo of $50 million odd.

Regards VAST this seems to be a guarded secret with management. PS promised to hold an r&d day earlier this year where we were to be briefed on VAST and other aspects of our company that all are keen for info. He has reneged on that promise and when l emailed him as to why he replied saying due to the split time was unavailable and some legal reasons associated with the demerger was making timing awkward.

Make of that what you will!!

Getting back on track my understanding is that vast has been licenced to Audeo but there's no detail. l'd like to know what the deal is. What's the fee and for what period? Earlier in a briefing PS stated they were looking at a spin off for vast.

Lots of unanswered questions.